MortonD.L., OllilaD.W., HsuehE.C., EssnerR., GuptaR.K.: Cytoreductive surgery and adjuvant immunotherapy: a new management paradigm for metastatic melanoma.CA Cancer J Clin, 49: 101–116, 1999.
2.
BarthA., WanekL.A., MortonD.L.: Prognostic factors in 1, 521 melanoma patients with distant metastases.J Am Coll Surg, 181: 193–201, 1995.
3.
OllilaD.W., MortonD.L.: Surgical resection as the treatment of choice for melanoma metastatic to the lung.Chest Surg Clin North Am, 8: 183–196, 1998.
4.
OllilaD.W., EssnerR., WanekL.A., MortonD.L.: Surgical resection for melanoma metastatic to the gastrointestinal tract.Arch Surg, 131: 975–980, 1996.
5.
TafraL., DaleP.S., WanekL.A., RammingK.P., MortonD.L.: Resection and adjuvant immunotherapy for melanoma metastatic to the lung and thorax.J Thorac Cardiovasc Surg, 110: 119–129, 1995.
6.
MortonD.L., FoshagL.J., HoonD.S., NizzeJ.A., FamatigaE., WanekL.A., ChangC., DavtyanD.G., GyptaR.K., ElashoffR.: Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.Ann Surg, 216: 463–482, 1992.
7.
ChanA.D., MortonD.L.: Active immunotherapy with allogeneic tumor cell vaccines: present status.Semin Oncol, 25: 611–622, 1998.
8.
MortonD.L., HsuehE.C., OllilaD.W., EssnerR., FoshagL.J., SternS.L., YeW.: Cytoreductive surgery and adjuvant postoperative immunotherapy with polyvalent melanoma vaccine enhances survival for stage IV melanoma: results of matched-pair analysis.Proc Am Soc Clin Oncol, 20: 355a, 2001.
9.
MortonD.L., BarthA.: Vaccine therapy for malignant melanoma.CA Cancer J Clin, 46: 225–244, 1996.
10.
JonesR.C., KelleyM.C., GuptaR.K., NizzeJ.A., YeeR., LeopoldoZ., QiS., SternS., MortonD.L.: Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model.Ann Surg Oncol, 3: 437–445, 1996.
11.
HsuehE.C., GuptaR.K., QiK., MortonD.L.: Correlation of specific immune responses with survival in patients receiving polyvalent melanoma cell vaccine.J Clin Oncol, 16: 2913–2920, 1998.
